These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17675894)

  • 1. C-reactive protein and the metabolic syndrome: useful addition to the cardiovascular risk profile?
    Szmitko PE; Verma S
    J Cardiometab Syndr; 2006; 1(1):66-9; quiz 70-1. PubMed ID: 17675894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome.
    Devaraj S; Valleggi S; Siegel D; Jialal I
    Curr Atheroscler Rep; 2010 Mar; 12(2):110-8. PubMed ID: 20425246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein.
    Malik S; Wong ND; Franklin S; Pio J; Fairchild C; Chen R
    Diabetes Care; 2005 Mar; 28(3):690-3. PubMed ID: 15735209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-reactive protein, metabolic syndrome, and insulin resistance in individuals with spinal cord injury.
    Lee MY; Myers J; Hayes A; Madan S; Froelicher VF; Perkash I; Kiratli BJ
    J Spinal Cord Med; 2005; 28(1):20-5. PubMed ID: 15832900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interrelationships between inflammation, C-reactive protein, and insulin resistance.
    Ndumele CE; Pradhan AD; Ridker PM
    J Cardiometab Syndr; 2006; 1(3):190-6. PubMed ID: 17679826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-reactive protein in cardiovascular risk assessment: a review of the evidence.
    Abraham J; Campbell CY; Cheema A; Gluckman TJ; Blumenthal RS; Danyi P
    J Cardiometab Syndr; 2007; 2(2):119-23. PubMed ID: 17684461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-reactive protein for cardiovascular risk assessment in the metabolic syndrome: response to Kholeif et al.
    Wong ND; Malik S
    Diabetes Care; 2005 Oct; 28(10):2598-9. PubMed ID: 16186320
    [No Abstract]   [Full Text] [Related]  

  • 8. C-reactive protein levels in patients at cardiovascular risk: EURIKA study.
    Halcox JP; Roy C; Tubach F; Banegas JR; Dallongeville J; De Backer G; Guallar E; Sazova O; Medina J; Perk J; Steg PG; Rodríguez-Artalejo F; Borghi C
    BMC Cardiovasc Disord; 2014 Feb; 14():25. PubMed ID: 24564178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidative stress and adverse adipokine profile characterize the metabolic syndrome in children.
    Kelly AS; Steinberger J; Kaiser DR; Olson TP; Bank AJ; Dengel DR
    J Cardiometab Syndr; 2006; 1(4):248-52. PubMed ID: 17679810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The prevalence of metabolic syndrome in middle-aged in Kaunas population].
    Gustiene O; Slapikas R; Klumbiene J; Sakalauskiene G; Kubilius R; Bagdzeviciūte S; Zaliūnas R
    Medicina (Kaunas); 2005; 41(10):867-76. PubMed ID: 16272835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High cardiovascular risk in patients with diabetes and the cardiometabolic syndrome: mandate for statin therapy.
    Gonzalez GL; Manrique CM; Sowers JR
    J Cardiometab Syndr; 2006; 1(3):178-83. PubMed ID: 17679817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-sensitivity C-reactive protein: a useful marker for cardiovascular disease risk prediction and the metabolic syndrome.
    Rifai N
    Clin Chem; 2005 Mar; 51(3):504-5. PubMed ID: 15738514
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?
    Robins SJ
    Curr Opin Lipidol; 2003 Dec; 14(6):575-83. PubMed ID: 14624134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are progranulin levels associated with polycystic ovary syndrome and its possible metabolic effects in adolescents and young women?
    Ersoy AO; Tokmak A; Ozler S; Oztas E; Ersoy E; Celik HT; Erdamar H; Yilmaz N
    Arch Gynecol Obstet; 2016 Aug; 294(2):403-9. PubMed ID: 27071619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic syndrome is strongly associated with chronic subclinical inflammation in patients achieving optimal low-density lipoprotein-cholesterol levels in secondary prevention of cardiovascular disease.
    Matsuo Y; Hashizume T; Shioji S; Akasaka T
    Circ J; 2008 Dec; 72(12):2046-50. PubMed ID: 18946171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of high-sensitivity assays for C-reactive protein in clinical practice.
    Musunuru K; Kral BG; Blumenthal RS; Fuster V; Campbell CY; Gluckman TJ; Lange RA; Topol EJ; Willerson JT; Desai MY; Davidson MH; Mora S
    Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):621-35. PubMed ID: 18711404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Test in Context: High-Sensitivity C-Reactive Protein.
    Ridker PM
    J Am Coll Cardiol; 2016 Feb; 67(6):712-723. PubMed ID: 26868696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The metabolic syndrome and cardiovascular disease: Part I.
    Jiamsripong P; Mookadam M; Honda T; Khandheria BK; Mookadam F
    Prev Cardiol; 2008; 11(3):155-61. PubMed ID: 18607151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.
    Ridker PM; Rifai N; Rose L; Buring JE; Cook NR
    N Engl J Med; 2002 Nov; 347(20):1557-65. PubMed ID: 12432042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.